Related Experiment Videos
Escaping out of the brain.
Joan Seoane1, Leticia De Mattos-Arruda2
1Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain. jseoane@vhio.net.
Cancer Discovery
|November 5, 2014
Summary
Circulating tumor cells are now detectable in glioblastoma patients' blood, thanks to advanced biomarker technology. This breakthrough offers new research avenues for understanding and treating this aggressive brain cancer.
Area of Science:
- Oncology
- Biomarker Discovery
- Molecular Diagnostics
Background:
- Glioblastoma is an aggressive brain cancer with limited treatment options.
- Accurate diagnostic and prognostic tools are crucial for managing glioblastoma.
- Circulating tumor cells (CTCs) are emerging biomarkers with potential clinical utility.
Purpose of the Study:
- To investigate the feasibility of detecting circulating tumor cells (CTCs) in the peripheral blood of glioblastoma patients.
- To explore the implications of CTC identification for glioblastoma research and clinical management.
Main Methods:
- Utilizing advanced circulating biomarker technologies.
- Analyzing peripheral blood samples from glioblastoma patients.
Main Results:
- Successful identification of circulating tumor cells in the peripheral blood of glioblastoma patients.
- Demonstration of technological advancements in biomarker detection.
Conclusions:
- Technological progress enables CTC detection in glioblastoma patients.
- This finding opens new research directions for understanding and clinically managing glioblastoma.